P eroxisome proliferator-activated receptor gamma (PPAR␥) is a member of the nuclear hormone receptor superfamily of ligand-activated transcription factors. These molecules regulate gene expression by binding to DNA in a heterodimeric complex with another nuclear hormone receptor, retinoid X receptor (RXR). 1, 2 Although the function of PPAR␥ is best defined for adipogenesis and glucose homeostasis, 3 it is also a key regulator of macrophage function. 4 -6 Because PPAR␥ targets genes involved in lipid metabolism, it is also implicated in cholesterol homeostasis. 7, 8 PPAR␥ is highly expressed in both macrophages and macrophage-derived foam cells, 9, 10 suggesting it plays a role in atherogenesis. Given the widespread clinical use of PPAR␥ ligands to improve insulin sensitivity in type 2 diabetes, it is critical to determine how PPAR␥ regulates macrophage function and foam cell formation. 11 PPAR␥ activators include naturally occurring ligands, such as polyunsaturated fatty acids and the prostanoid 15-deoxy-␦ 12,13 -prostaglandin J2, 3 as well as the insulin-sensitizing drugs known as thiazolidinediones (TZDs). 12 On ligand binding, PPAR␥ undergoes a conformational change, enabling heterodimerization with its obligate partner, RXR. This complex can then bind to a direct repeat consensus sequence or PPAR␥ response element (PPRE) located in the promoter region of target genes. 14 The PPAR␥:RXR heterodimer can also be activated by an RXR-specific ligand, alone such as 9-cis retinoic acid (9cRA), and when used in combination with a PPAR␥ ligand, the activity of the dimer is enhanced further. 13 The scavenger receptor, CD36, contains a PPRE in its promoter region and is a target of PPAR␥ activation. 7 In PPAR␥-null macrophages, basal expression of CD36 and its stimulation by TZDs was significantly reduced. 15 CD36 mediates a significant proportion of oxidized (ox) lipoprotein uptake in cultured macrophages and in CD36-null mice the development of atherosclerosis was reduced. 16 In addition, a feed-forward loop has been described, whereby macrophage uptake of oxLDL provides ligands for PPAR␥, including 9-hydroxyoctadecadienoic acid and 15-hydroxyoctadecadienoic acid, thereby perpetuating CD36 expression and thus potentially increasing oxLDL uptake. 17, 18 Consequently, PPAR␥ activation was predicted to promote macrophage foam cell formation and by extension atherogenesis.
However, PPAR␥ activation by rosiglitazone or troglitazone reduces atherosclerotic lesions in LDL receptor (LDLR)-null 19, 20 and apoE-null mice, 21 despite an increase in macrophage CD36 expression. 19, 21 Furthermore, increased lesions were observed in macrophage-specific PPAR␥-null mice, generated by transplantation of bone marrow from PPAR␥-null mice to LDLR-null mice. 22 One explanation for the protective effect of PPAR␥ activation is that enhanced CD36 expression in adipocytes could provide a relatively benign sink for potentially deleterious oxLDL. 23 Other potential mechanisms have been proposed, including attenuation of hyperinsulinemia and/or hyperglycemia; increase of plasma HDL cholesterol concentration; 21 and a reduction in adhesion molecules, chemokine receptors, and chemokines, such as monocyte chemotactic protein. 8, 20 Still uncertain in these animal models is the role of macrophage foam cell formation in the PPAR␥-induced inhibition of atherogenesis.
The results of in vitro studies are inconclusive as to whether PPAR␥ activation increases oxLDL uptake. 7, 15 In THP-1 macrophages, PPAR␥ and RXR ligands increased CD36 expression, leading to enhanced DiI-labeled oxLDL uptake, 7 whereas in wild-type embryonic stem cells (ES), [
125 I]oxLDL uptake was unaffected by a PPAR␥ or RXR ligand alone, although a 20% decrease with both ligands together was observed. 15 However, oxLDL uptake does not specifically measure CD36 activity but rather the activity of all scavenger receptors that recognize oxLDL, including SRAI/II. PPAR␥ ligands do not appear to affect SRAI/II mRNA expression; however, protein levels were reduced in troglitazone-treated wild-type ES cells, 15 a result that would predict a decrease in oxLDL uptake. Nevertheless, the impact of PPAR␥ activation on macrophage expression of both CD36 and SRAI/II and how this influences net ox lipoprotein uptake remains to be clearly established. Furthermore, the link between macrophage PPAR␥ activation, oxidized lipoprotein-induced CE accumulation and subsequent foam cell formation has yet to be fully elucidated. PPAR␥ activators also modulate cholesterol efflux by regulating the gene expression of ATP-binding cassette proteins A1 (ABCA1) and G1 (ABCG1). 22, 24, 25 The integral role of ABCA1 in regulating cellular cholesterol transport is exemplified by loss-of-function mutations causing Tangier disease, which is characterized by significant cholesterol accumulation in macrophages. 26, 27 ABCA1 expression is upregulated by PPAR␥ ligands through a transcriptional cascade mediated by the nuclear hormone receptor, liver X receptor (LXR␣). 22 The LXR␣ gene contains a PPRE, so that on PPAR␥ activation, LXR␣ expression is induced. Ligandbound LXR␣ heterodimerizes with RXR and binds the LXRRE in the ABCA1 promoter, thereby increasing its expression and enhancing cellular cholesterol efflux to HDL and apoAI. PPAR␥ activation in macrophages stimulates ABCA1 expression and promotes cholesterol efflux from lipid-loaded cells, a result that has been confirmed by the lack of effect of PPAR␥ ligands in PPAR␥-null cells. 25 Thus, the overall consequence of PPAR␥ ligands on macrophage cholesteryl ester (CE) accumulation and hence foam cell formation would be the net effect on the competing processes of lipoprotein uptake and cholesterol efflux. Therefore, our objectives were to examine the impact of PPAR␥ and/or RXR ligands on cellular cholesterol accumulation induced by ox lipoproteins in cultured macrophages and to elucidate the mechanisms involved. Our results demonstrate that macrophage CE accumulation induced by ox lipoproteins is significantly reduced by TZDs. In addition, the RXR ligand, 9cRA, reduced CE accumulation, and this effect was amplified when combined with ciglitazone. Ciglitazone alone or in combination with 9cRA significantly enhanced both expression of ABCA1 and ABCG1 and efflux of cholesterol to lipoprotein-deficient serum (LPDS) apoAI and HDL 3 . Despite a marked induction in CD36 expression, uptake of [ 125 I]oxLDL was only modestly increased. This was caused by a decrease in SRAI/II activity by PPAR␥ and RXR ligands. On balance, PPAR␥ and RXR activation reduces the CE accumulation in macrophages induced by ox lipoproteins as the result of an overriding impact on ABCA1-mediated cholesterol efflux.
Methods
Please see online data supplement (which can be accessed at http://atvb.ahajournals.org) for materials and methods.
Results

OxHTG
VLDL and their remnants induced lipid accumulation in THP-1 human macrophages: Incubation of THP-1 human macrophages with oxHTG-VLDL and oxREM induced CE mass by 6.2-and 6.4-fold (both PϽ0.05) and triglyceride (TG) mass by 2.7-and 3.0-fold (both PϽ0.05), respectively ( Figure 1A and B) . Similarly, oxLDL and AcLDL induced cellular CE accumulation by 5.8-and 11-fold (PϽ0.05), with neither lipoprotein inducing TG mass accumulation. Cellular free cholesterol (FC) mass was significantly enhanced by all modified lipoprotein preparations (1.5-to 2.2-fold; Figure  1C ), a result consistent with the observation that cholesterol derived from ox lipoproteins is retained within the lysosomal compartment for an extended period. 28 
Ligand Activation of PPAR␥ Inhibited CE Mass Induced by Modified Lipoproteins
Pretreatment of THP-1 macrophages with ciglitazone significantly inhibited cellular CE mass induced by oxHTG-VLDL, oxREM, or oxLDL by Ϫ40%, Ϫ38%, and Ϫ47% (all, PϽ0.05), respectively, compared with lipoprotein alone (Figure 1A) . The effect of ciglitazone on CE mass was dose dependent (Figure 2 ). In addition, another TZD, troglitazone, inhibited cellular CE accumulation induced by oxHTG-VLDL in a dose-dependent manner from Ϫ42% to Ϫ68% (PϽ0.05; Figure 2 ).
In contrast, TG mass induced by either lipoprotein preparation was unaffected by pretreatment of cells with either TZD ( Figure 1B and data not shown). Also, in the absence of ox lipoprotein the TZDs had no significant effect on cellular CE content.
Ligand Activation of RXR Inhibited CE Mass Induced by Modified Lipoproteins
Pretreatment of macrophages with 9cRA significantly inhibited oxHTG-VLDL-, oxREM-, and oxLDL-induced CE mass by Ϫ36%, Ϫ33%, and Ϫ44% (all PϽ0.05), respectively, compared with lipoprotein alone ( Figure 1A ). The effect of 9cRA was dose dependent, with inhibition of CE mass induced by oxHTG-VLDL ranging from Ϫ15% to Ϫ50% (PϽ0.05, Figure 2 ). In contrast, 9cRA did not affect TG mass induced by any ox lipoproteins tested ( Figure 1B ).
Combined RXR and PPAR␥ Activation Markedly Reduced CE Accumulation Induced by Ox Lipoproteins
To further enhance the activity of the PPAR␥:RXR heterodimer, THP-1 cells were pretreated with ciglitazone and 9cRA together. These ligands significantly reduced CE accumulation induced by oxHTG-VLDL, oxREM, or oxLDL by Ϫ69%, Ϫ52% and Ϫ63% (all PϽ0.05, Figure 1A ), respectively, compared with lipoprotein alone. This decrease in CE mass was markedly enhanced compared with the inhibition observed by either PPAR␥ or RXR ligand alone, suggesting a synergistic effect. In contrast, TG accumulation induced by ox lipoproteins was unaffected by the combination of ligands ( Figure 1B ).
In addition, the increases in FC mass induced by ox lipoproteins alone were significantly reduced by pretreatment of macrophages with both ciglitazone and 9cRA to levels similar to those observed in control cells ( Figure 1C ).
PPAR␥ and RXR Activation Inhibited oxHTG-VLDL-Induced CE Accumulation in LDLR-Null and Wild-Type MPMs
TZD treatment of LDLR-null mice inhibits formation of early atherosclerotic lesions in vivo. 19, 20 To determine whether this decrease in atherosclerosis may be mediated through a PPAR␥-induced inhibition of macrophage foam cell formation, MPMs were isolated from both LDLR-null and wildtype mice. OxHTG-VLDL induced CE accumulation in both wild-type and LDLR-null MPMs by approximately 20-fold. Pretreatment of MPMs with ciglitazone significantly inhibited CE accumulation induced by oxHTG-VLDL by Ϫ35% and Ϫ20% in wild-type and LDLR-null MPMs, respectively (both PϽ0.05; see online Figure I , which can be accessed at http://atvb.ahajournals.org). Preincubation with 9cRA also significantly inhibited oxHTG-VLDL-induced CE accumulation in both wild-type and LDLR-null MPMs by 23% and 27%, respectively (PϽ0.05). The concentration of 9cRA required to achieve this effect was higher than that used in THP-1 cells. This was most likely caused by the low level of expression of PPAR␥ in nonthioglycollate-stimulated MPMs. The addition of both ciglitazone and 9cRA together did not further reduce CE accumulation in either cell type.
PPAR␥ and RXR Activation Regulate CD36 and SRAI/II Activity
Macrophage uptake of oxHTG-VLDL is mediated by both CD36 and SRAI/II. 29, 30 As demonstrated in the Table, CD36 Figure I ). 30 Therefore, we determined the contribution of SRAI/II expression to the PPAR␥-mediated decrease in CE accumulation induced by ox lipoproteins by isolating MPMs from SRAI/II-null mice and their controls and pretreating them with PPAR␥ ligands. In control cells, ciglitazone and 9cRA alone or in combination significantly inhibited oxHTG-VLDL-induced CE accumulation by Ϫ27% to Ϫ36% (PϽ0.05, Figure I ). However, in the absence of SRAI/II expression, these ligands alone or in combination, only reduced CE accumulation induced by oxHTG-VLDL by Ϫ15% to Ϫ22% (PϽ0.05). Therefore, decreased SRAI/II activity mediates, in part, the reduction in CE mass induced by PPAR␥ and RXR ligands.
Consistent with these findings is the effect of PPAR␥ and RXR ligands on cellular uptake of [ 125 I]AcLDL, a modified lipoprotein with ligand specificity for SRAI/II. In THP-1 cells, [
125 I]AcLDL binding, uptake, and degradation were significantly inhibited by ciglitazone by Ϫ35% and Ϫ24%, respectively (PϽ0.05; Figure 3 ). In addition, 9cRA inhibited [ 125 I]AcLDL binding, uptake and degradation by Ϫ23% and Ϫ21%, respectively (PϽ0.05), an effect slightly enhanced by combining the ligands. This result explains the modest increase in oxLDL uptake in that the increased CD36 expression is offset by a decrease in SRAI/II activity. Furthermore AcLDL-induced cellular CE accumulation in THP-1 cells was significantly inhibited by ciglitazone and 9cRA alone or in combination by Ϫ40% to Ϫ70% (PϽ0.05, Figure 1 ). Collectively these finding indicate that decreased SRAI/II activity contributes to the inhibition of foam cell formation induced by ligands for PPAR␥ and RXR.
PPAR␥ and RXR Activation Enhanced Macrophage Cholesterol Transport Genes and Efflux
Although ciglitazone and 9cRA increased ox lipoprotein uptake, CE mass accumulation induced by these lipoproteins was significantly reduced by both ligands. Therefore, we addressed the effects of PPAR␥ and RXR activation on cholesterol efflux. ABCA1 and ABCG1 transporters are responsible for the removal of cellular cholesterol stores. Preincubation of macrophages with ciglitazone induced ABCA1 and ABCG1 mRNA expression by 1.7-and 1.8-fold (PϽ0.05; Table) , respectively. Similarly 9cRA induced ABCA1 and ABCG1 expression (1.4-fold for both; PϽ0.05). Consistent with changes in ABC mRNA expression, pretreatment of cells with ciglitazone or 9cRA significantly increased cholesterol efflux to apoAI by 1.3-fold (PϽ0.05 for both; Figure 4A ). The combination of ciglitazone and 9cRA increased cholesterol efflux by a further 40%. Ciglitazone and 9cRA produced similar increases in cholesterol efflux to HDL 3 . Because the lipoprotein-induced CE accumulation experiments were performed in DMEM containing only LPDS, we determined whether these ligands could stimulate cholesterol efflux to LPDS, which contains apoAI. As shown in Figure 4A , addition of LPDS to the media increased efflux to cholesterol by 3-fold (PϽ0.05) over BSA alone. Importantly, ciglitazone or 9cRA alone further increased cellular cholesterol efflux to LPDS by 23% and 11%, respectively (both PϽ0.05). Ciglitazone plus 9cRA increased efflux to LPDS by an additional 20%. Thus, enhanced cholesterol efflux is part of the mechanism whereby these ligands block macrophage foam cell formation.
Ciglitazone and 9cRA-Mediated Induction of Cholesterol Efflux Is Mediated Through PPAR␥ and LXR
To demonstrate directly that ciglitazone and 9cRA mediate cholesterol efflux through activation of PPAR␥ and subsequently LXR, the effects of known antagonists of PPAR␥ (bisphenol A diglycidyl ether; BADGE) 31 and LXR (5␣,6␣-epoxycholesterol-3-sulfate, ECHS) 32 were examined in the cholesterol efflux assay. Incubation of macrophages with BADGE alone had no significant effect on cholesterol efflux to apoAI ( Figure 4B ). However, co-incubation of BADGE and ciglitazone completely blocked the ciglitazone-induced 30% increase in cholesterol efflux to apoAI. In contrast, the co-incubation of BADGE and 9cRA had no effect on the 9cRA-induced increase in cholesterol efflux to apoAI, suggesting that 9cRA enhances efflux through a mechanism independent of PPAR␥. Therefore, when cells were incubated with ciglitazone, 9cRA, and BADGE, the amount of cholesterol efflux to apoAI was reduced by 18% (PϽ0.05), a value similar to that observed in the presence of 9cRA alone plus BADGE.
In contrast with BADGE, the incubation of macrophages with the LXR antagonist (ECHS) alone showed a significant 20% decrease in cholesterol efflux to apoAI ( Figure 4B ). This result is most likely because of the inhibition of the effects of endogenous LXR ligands. Co-incubation of cells with ciglitazone and ECHS completely blocked the 30% induction of cholesterol efflux to apoAI by ciglitazone. This finding indicates that stimulation of macrophage cholesterol efflux by PPAR␥ activation occurs through LXR. ECHS also completely blocked the enhancement of cholesterol efflux to apoAI induced by 9cRA alone or in combination with ciglitazone, suggesting that 9cRA increases cholesterol efflux through stimulation of the LXR:RXR dimer. The combination of BADGE and ECHS in the presence of either ligand alone or together did not further reduce cholesterol efflux to ECHS alone. Therefore, PPAR␥ and RXR ligands mediate enhanced cholesterol efflux to apoAI through a PPAR␥:RXR-sensitive pathway.
To further demonstrate the importance of the PPAR␥:LXR:ABCA1 pathway on foam cell formation, we also used the LXR antagonist in the lipid mass assay. As shown in Figure 5 , ECHS completely blocked the ciglitazoneand 9cRA-induced reduction in CE mass in macrophages incubated with oxHTG-VLDL. This suggests that the primary pathway mediating the PPAR␥ inhibition in CE accumulation induced by ox lipoproteins is enhancement of cholesterol efflux through a PPAR␥:LXR:ABCA1 transcriptional cascade.
Discussion
In this report we demonstrate that PPAR␥ ligands, namely the TZDs troglitazone and ciglitazone, and an RXR ligand, namely 9cRA, significantly reduced macrophage CE accumulation induced by atherogenic lipoproteins, namely ox-HTG-VLDL, their remnants, and LDL. To our knowledge this is the first report to demonstrate that PPAR␥ and RXR ligands alone or in combination markedly decrease macrophage CE accumulation, thereby inhibiting foam cell forma- 
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tion in vitro. Our findings support a mechanism whereby PPAR␥ and RXR ligands enhance ABCA1-and ABCG1-mediated cellular cholesterol efflux, more than compensating for any increase in the cellular cholesterol pool as a result of increased CD36 scavenger receptor expression and ox lipoprotein uptake.
Since the discovery that PPAR␥ ligands upregulate CD36 expression, 7 there has been great interest as to whether this leads to enhanced foam cell formation, especially because TZDs are widely prescribed to diabetic patients, a population at high risk of atherosclerosis. 11 However, because of inconsistent reports on oxLDL uptake and uncertainty regarding effects on cholesterol efflux, 7, 15, 24, 25 the outcome of ciglitazone and 9cRA treatment on lipoprotein-induced cholesterol mass accumulation in macrophages was difficult to predict. However, it was evident from in vivo mouse studies that PPAR␥ and RXR ligands decrease atherosclerotic lesion formation. 19 -21,25,33 In this study, we show only a modest enhancement in macrophage [
125 I]oxLDL uptake induced by ciglitazone and 9cRA treatment, a finding consistent with Tontonoz et al. 7 However, Moore et al 15 24 Those authors demonstrated that in THP-1 macrophages and human primary macrophages, rosiglitazone treatment did not affect cholesterol accumulation induced by AcLDL or oxLDL. It is unclear whether this difference is attributable to rosiglitazone use rather than ciglitazone or troglitazone or to some other mechanism. This lack of effect of rosiglitazone on oxLDL-and AcLDL-induced macrophage cholesterol accumulation is surprising, because in separate experiments, ABCA1 expression and apoAI-mediated cholesterol efflux from cholesterol-loaded cells were significantly increased, a result that concurs with our findings. The possible absence of a cholesterol acceptor in the culture medium could have prevented cholesterol efflux during incubations of macrophages with AcLDL or oxLDL. 24 In the present study incubations of macrophages with either oxLDL or AcLDL included LPDS, which we have previously demonstrated to be an effective acceptor of cellular cholesterol. 30 In addition to modulating scavenger receptor expression, PPAR␥ and RXR are important regulators of macrophage cholesterol efflux. 24, 25, 35 Cholesterol efflux to acceptors is mediated by both specific energy-requiring processes and nonspecific passive diffusion. 36 Our results clearly demonstrate that ciglitazone and 9cRA, either alone or in combination, can stimulate the expression of both ABCA1 and ABCG1, resulting in enhanced efflux of cellular cholesterol to apoAI and HDL 3 . A key observation of this study was that ciglitazone and 9cRA enhanced cholesterol efflux to LPDS. This likely explains the inhibition of CE accumulation in THP-1 and MPMs incubated with ox lipoproteins. Despite enhanced ox lipoprotein uptake with increased CD36 expression, more cholesterol was being effluxed to LPDS (probably because of its content of apoAI 30 ), in response to ciglitazone and 9cRA. Our results agree with those of others who demonstrated that rosiglitazone alone or in combination with the RXR ligand LG268 stimulated expression of ABCA1 and ABCG1 and cholesterol efflux to apoAI from THP-1 cells, MPMs, or human monocyte-derived macrophages. 22, 24 However, those authors did not demonstrate that this specifically decreases ox lipoprotein-induced cellular CE accumulation. Our findings contrast those of Akiyama et al, 25 who found that in thioglycollate-elicited MPMs, troglitazone decreased the expression of ABCA1 and reduced cholesterol efflux to HDL. Furthermore, those authors showed that, unexpectedly, ciglitazone, rosiglitazone, and pioglitazone had no effect on ABCA1 expression. 25 Reasons for such disparities between studies are not readily apparent but may be related to cell type. Again, the effect of these TZDs on foam cell formation was not directly determined.
Several lines of experimental evidence have shown that PPAR␥ regulates ABCA1 and ABCG1 expression through a transcriptional cascade involving LXR. 22, 25 We wanted to demonstrate that this cascade applied to THP-1 cells and, importantly, to establish that ABCA1/ABCG1-mediated cholesterol efflux was the predominant mechanism underlying reduced foam cell formation. By using antagonists for both PPAR␥ and LXR, 31, 32 we showed that either antagonist completely blocks ciglitazone-enhanced cholesterol efflux to apoAI. This confirms that PPAR␥ activation of ABCA1-mediated cholesterol efflux requires LXR. However, the PPAR␥ antagonist could not inhibit the effect of 9cRA. Macrophage ABCA1 expression is upregulated by both PPAR␥ and LXR agonists (Table) . 24, 37 However, RXR is the obligate partner for both PPAR␥ and LXR. Therefore, it was not known whether 9cRA mediated enhanced cholesterol efflux to apoAI through activation of the PPAR␥ or LXR dimer. Our results demonstrate conclusively that the 9cRA-induced increase in cholesterol efflux to apoAI was specific to the LXR antagonist, indicating that RXR ligands enhance efflux primarily through an LXR sensitive pathway. Evidence that the PPAR␥:LXR:ABCA1 pathway regulates foam cell formation in vitro comes from demonstrating the reversal of the ciglitazone-induced CE mass reduction by an LXR antagonist ( Figure 5 ).
Our observation that PPAR␥ and RXR ligands can inhibit foam cell formation induced by ox lipoproteins specifies an important mechanism underlying the reduced atherosclerosis in mice treated with TZDs or RXR ligands. 20, 21, 33 Although PPAR␥ and RXR ligands tend to stimulate lipoprotein uptake, their ability to stimulate ABCA1-and ABCG1-mediated cholesterol efflux predominates in our macrophage model. These observations imply that the normal physiological response of arterial wall macrophages to PPAR␥ ligands derived from ox lipoproteins is to increase CD36-mediated uptake of these lipoproteins, thereby relieving the arterial wall of the immunological pressure induced by ox lipoproteins. Simultaneously, this would fuel a mechanism whereby the excess intracellular cholesterol is redirected for efflux. In this case, cholesterol esterification would only be stimulated as a protective effect when cholesterol efflux pathways were saturated. 38 Nonetheless, our study demonstrates that the addition of exogenous PPAR␥ and/or RXR ligands over and above those ligands derived from oxidized lipoproteins would further stimulate cholesterol efflux through the reverse cholesterol transport pathway. Ultimately, this mechanism would contribute to a reduction in atherogenesis. 
